CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. Bargaining power of suppliers
3.3.2. Bargaining power of buyers
3.3.3. Threat of substitutes
3.3.4. Threat of new entrants
3.3.5. Intensity of rivalry
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Increasing incidence of motion sickness
3.4.1.2. Surge in adoption of motion sickness treatments
3.4.1.3. Surge in product approval and product launches by the key players
3.4.2. Restraints
3.4.2.1. Presence of alternate solution for motion sickness treatment
3.4.2.2. Limited awareness and knowledge about motion sickness
3.4.3. Opportunities
3.4.3.1. Growth opportunity in emerging markets
3.5. COVID-19 Impact Analysis on the market
CHAPTER 4: MOTION SICKNESS TREATMENT MARKET, BY DRUG CLASS
4.1. Overview
4.1.1. Market size and forecast
4.2. Antihistamines
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Anticholinergics
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.4. Others
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
CHAPTER 5: MOTION SICKNESS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Oral
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Others
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
CHAPTER 6: MOTION SICKNESS TREATMENT MARKET, BY DISTRIBUTION CHANNEL
6.1. Overview
6.1.1. Market size and forecast
6.2. Hospital Pharmacies
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Drug Store and Retail Pharmacies
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
6.4. Online Pharmacies
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market share analysis by country
CHAPTER 7: MOTION SICKNESS TREATMENT MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast By Region
7.2. North America
7.2.1. Key trends and opportunities
7.2.2. Market size and forecast, by Drug Class
7.2.3. Market size and forecast, by Route of Administration
7.2.4. Market size and forecast, by Distribution Channel
7.2.5. Market size and forecast, by country
7.2.5.1. U.S.
7.2.5.1.1. Key market trends, growth factors and opportunities
7.2.5.1.2. Market size and forecast, by Drug Class
7.2.5.1.3. Market size and forecast, by Route of Administration
7.2.5.1.4. Market size and forecast, by Distribution Channel
7.2.5.2. Canada
7.2.5.2.1. Key market trends, growth factors and opportunities
7.2.5.2.2. Market size and forecast, by Drug Class
7.2.5.2.3. Market size and forecast, by Route of Administration
7.2.5.2.4. Market size and forecast, by Distribution Channel
7.2.5.3. Mexico
7.2.5.3.1. Key market trends, growth factors and opportunities
7.2.5.3.2. Market size and forecast, by Drug Class
7.2.5.3.3. Market size and forecast, by Route of Administration
7.2.5.3.4. Market size and forecast, by Distribution Channel
7.3. Europe
7.3.1. Key trends and opportunities
7.3.2. Market size and forecast, by Drug Class
7.3.3. Market size and forecast, by Route of Administration
7.3.4. Market size and forecast, by Distribution Channel
7.3.5. Market size and forecast, by country
7.3.5.1. Germany
7.3.5.1.1. Key market trends, growth factors and opportunities
7.3.5.1.2. Market size and forecast, by Drug Class
7.3.5.1.3. Market size and forecast, by Route of Administration
7.3.5.1.4. Market size and forecast, by Distribution Channel
7.3.5.2. France
7.3.5.2.1. Key market trends, growth factors and opportunities
7.3.5.2.2. Market size and forecast, by Drug Class
7.3.5.2.3. Market size and forecast, by Route of Administration
7.3.5.2.4. Market size and forecast, by Distribution Channel
7.3.5.3. UK
7.3.5.3.1. Key market trends, growth factors and opportunities
7.3.5.3.2. Market size and forecast, by Drug Class
7.3.5.3.3. Market size and forecast, by Route of Administration
7.3.5.3.4. Market size and forecast, by Distribution Channel
7.3.5.4. Italy
7.3.5.4.1. Key market trends, growth factors and opportunities
7.3.5.4.2. Market size and forecast, by Drug Class
7.3.5.4.3. Market size and forecast, by Route of Administration
7.3.5.4.4. Market size and forecast, by Distribution Channel
7.3.5.5. Spain
7.3.5.5.1. Key market trends, growth factors and opportunities
7.3.5.5.2. Market size and forecast, by Drug Class
7.3.5.5.3. Market size and forecast, by Route of Administration
7.3.5.5.4. Market size and forecast, by Distribution Channel
7.3.5.6. Rest of Europe
7.3.5.6.1. Key market trends, growth factors and opportunities
7.3.5.6.2. Market size and forecast, by Drug Class
7.3.5.6.3. Market size and forecast, by Route of Administration
7.3.5.6.4. Market size and forecast, by Distribution Channel
7.4. Asia-Pacific
7.4.1. Key trends and opportunities
7.4.2. Market size and forecast, by Drug Class
7.4.3. Market size and forecast, by Route of Administration
7.4.4. Market size and forecast, by Distribution Channel
7.4.5. Market size and forecast, by country
7.4.5.1. Japan
7.4.5.1.1. Key market trends, growth factors and opportunities
7.4.5.1.2. Market size and forecast, by Drug Class
7.4.5.1.3. Market size and forecast, by Route of Administration
7.4.5.1.4. Market size and forecast, by Distribution Channel
7.4.5.2. China
7.4.5.2.1. Key market trends, growth factors and opportunities
7.4.5.2.2. Market size and forecast, by Drug Class
7.4.5.2.3. Market size and forecast, by Route of Administration
7.4.5.2.4. Market size and forecast, by Distribution Channel
7.4.5.3. India
7.4.5.3.1. Key market trends, growth factors and opportunities
7.4.5.3.2. Market size and forecast, by Drug Class
7.4.5.3.3. Market size and forecast, by Route of Administration
7.4.5.3.4. Market size and forecast, by Distribution Channel
7.4.5.4. Australia
7.4.5.4.1. Key market trends, growth factors and opportunities
7.4.5.4.2. Market size and forecast, by Drug Class
7.4.5.4.3. Market size and forecast, by Route of Administration
7.4.5.4.4. Market size and forecast, by Distribution Channel
7.4.5.5. South Korea
7.4.5.5.1. Key market trends, growth factors and opportunities
7.4.5.5.2. Market size and forecast, by Drug Class
7.4.5.5.3. Market size and forecast, by Route of Administration
7.4.5.5.4. Market size and forecast, by Distribution Channel
7.4.5.6. Rest of Asia-Pacific
7.4.5.6.1. Key market trends, growth factors and opportunities
7.4.5.6.2. Market size and forecast, by Drug Class
7.4.5.6.3. Market size and forecast, by Route of Administration
7.4.5.6.4. Market size and forecast, by Distribution Channel
7.5. LAMEA
7.5.1. Key trends and opportunities
7.5.2. Market size and forecast, by Drug Class
7.5.3. Market size and forecast, by Route of Administration
7.5.4. Market size and forecast, by Distribution Channel
7.5.5. Market size and forecast, by country
7.5.5.1. Brazil
7.5.5.1.1. Key market trends, growth factors and opportunities
7.5.5.1.2. Market size and forecast, by Drug Class
7.5.5.1.3. Market size and forecast, by Route of Administration
7.5.5.1.4. Market size and forecast, by Distribution Channel
7.5.5.2. Saudi Arabia
7.5.5.2.1. Key market trends, growth factors and opportunities
7.5.5.2.2. Market size and forecast, by Drug Class
7.5.5.2.3. Market size and forecast, by Route of Administration
7.5.5.2.4. Market size and forecast, by Distribution Channel
7.5.5.3. South Africa
7.5.5.3.1. Key market trends, growth factors and opportunities
7.5.5.3.2. Market size and forecast, by Drug Class
7.5.5.3.3. Market size and forecast, by Route of Administration
7.5.5.3.4. Market size and forecast, by Distribution Channel
7.5.5.4. Rest of LAMEA
7.5.5.4.1. Key market trends, growth factors and opportunities
7.5.5.4.2. Market size and forecast, by Drug Class
7.5.5.4.3. Market size and forecast, by Route of Administration
7.5.5.4.4. Market size and forecast, by Distribution Channel
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top player positioning, 2021
CHAPTER 9: COMPANY PROFILES
9.1. Prestige Consumer Healthcare Inc.
9.1.1. Company overview
9.1.2. Key Executives
9.1.3. Company snapshot
9.1.4. Operating business segments
9.1.5. Product portfolio
9.1.6. Business performance
9.2. Baxter International Inc.
9.2.1. Company overview
9.2.2. Key Executives
9.2.3. Company snapshot
9.2.4. Operating business segments
9.2.5. Product portfolio
9.2.6. Business performance
9.3. Novartis AG
9.3.1. Company overview
9.3.2. Key Executives
9.3.3. Company snapshot
9.3.4. Operating business segments
9.3.5. Product portfolio
9.3.6. Business performance
9.4. WellSpring Pharmaceutical Corporation
9.4.1. Company overview
9.4.2. Key Executives
9.4.3. Company snapshot
9.4.4. Operating business segments
9.4.5. Product portfolio
9.5. Amneal Pharmaceuticals LLC
9.5.1. Company overview
9.5.2. Key Executives
9.5.3. Company snapshot
9.5.4. Operating business segments
9.5.5. Product portfolio
9.5.6. Business performance
9.6. Abbott Laboratories
9.6.1. Company overview
9.6.2. Key Executives
9.6.3. Company snapshot
9.6.4. Operating business segments
9.6.5. Product portfolio
9.6.6. Business performance
9.7. Sun Pharmaceutical Industries Ltd.
9.7.1. Company overview
9.7.2. Key Executives
9.7.3. Company snapshot
9.7.4. Operating business segments
9.7.5. Product portfolio
9.7.6. Business performance
9.8. Viatris Inc.
9.8.1. Company overview
9.8.2. Key Executives
9.8.3. Company snapshot
9.8.4. Operating business segments
9.8.5. Product portfolio
9.8.6. Business performance
9.8.7. Key strategic moves and developments
9.9. Teva Pharmaceutical Industries Limited
9.9.1. Company overview
9.9.2. Key Executives
9.9.3. Company snapshot
9.9.4. Operating business segments
9.9.5. Product portfolio
9.9.6. Business performance
9.10. Zydus Lifesciences Limited
9.10.1. Company overview
9.10.2. Key Executives
9.10.3. Company snapshot
9.10.4. Operating business segments
9.10.5. Product portfolio
9.10.6. Business performance
9.10.7. Key strategic moves and developments
TABLE 01. GLOBAL MOTION SICKNESS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 02. MOTION SICKNESS TREATMENT MARKET FOR ANTIHISTAMINES, BY REGION, 2021-2031 ($MILLION)
TABLE 03. MOTION SICKNESS TREATMENT MARKET FOR ANTICHOLINERGICS, BY REGION, 2021-2031 ($MILLION)
TABLE 04. MOTION SICKNESS TREATMENT MARKET FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
TABLE 05. GLOBAL MOTION SICKNESS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 06. MOTION SICKNESS TREATMENT MARKET FOR ORAL, BY REGION, 2021-2031 ($MILLION)
TABLE 07. MOTION SICKNESS TREATMENT MARKET FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
TABLE 08. GLOBAL MOTION SICKNESS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 09. MOTION SICKNESS TREATMENT MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
TABLE 10. MOTION SICKNESS TREATMENT MARKET FOR DRUG STORE AND RETAIL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
TABLE 11. MOTION SICKNESS TREATMENT MARKET FOR ONLINE PHARMACIES, BY REGION, 2021-2031 ($MILLION)
TABLE 12. MOTION SICKNESS TREATMENT MARKET, BY REGION, 2021-2031 ($MILLION)
TABLE 13. NORTH AMERICA MOTION SICKNESS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 14. NORTH AMERICA MOTION SICKNESS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 15. NORTH AMERICA MOTION SICKNESS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 16. NORTH AMERICA MOTION SICKNESS TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 17. U.S. MOTION SICKNESS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 18. U.S. MOTION SICKNESS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 19. U.S. MOTION SICKNESS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 20. CANADA MOTION SICKNESS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 21. CANADA MOTION SICKNESS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 22. CANADA MOTION SICKNESS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 23. MEXICO MOTION SICKNESS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 24. MEXICO MOTION SICKNESS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 25. MEXICO MOTION SICKNESS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 26. EUROPE MOTION SICKNESS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 27. EUROPE MOTION SICKNESS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 28. EUROPE MOTION SICKNESS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 29. EUROPE MOTION SICKNESS TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 30. GERMANY MOTION SICKNESS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 31. GERMANY MOTION SICKNESS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 32. GERMANY MOTION SICKNESS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 33. FRANCE MOTION SICKNESS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 34. FRANCE MOTION SICKNESS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 35. FRANCE MOTION SICKNESS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 36. UK MOTION SICKNESS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 37. UK MOTION SICKNESS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 38. UK MOTION SICKNESS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 39. ITALY MOTION SICKNESS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 40. ITALY MOTION SICKNESS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 41. ITALY MOTION SICKNESS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 42. SPAIN MOTION SICKNESS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 43. SPAIN MOTION SICKNESS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 44. SPAIN MOTION SICKNESS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 45. REST OF EUROPE MOTION SICKNESS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 46. REST OF EUROPE MOTION SICKNESS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 47. REST OF EUROPE MOTION SICKNESS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 48. ASIA-PACIFIC MOTION SICKNESS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 49. ASIA-PACIFIC MOTION SICKNESS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 50. ASIA-PACIFIC MOTION SICKNESS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 51. ASIA-PACIFIC MOTION SICKNESS TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 52. JAPAN MOTION SICKNESS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 53. JAPAN MOTION SICKNESS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 54. JAPAN MOTION SICKNESS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 55. CHINA MOTION SICKNESS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 56. CHINA MOTION SICKNESS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 57. CHINA MOTION SICKNESS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 58. INDIA MOTION SICKNESS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 59. INDIA MOTION SICKNESS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 60. INDIA MOTION SICKNESS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 61. AUSTRALIA MOTION SICKNESS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 62. AUSTRALIA MOTION SICKNESS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 63. AUSTRALIA MOTION SICKNESS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 64. SOUTH KOREA MOTION SICKNESS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 65. SOUTH KOREA MOTION SICKNESS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 66. SOUTH KOREA MOTION SICKNESS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 67. REST OF ASIA-PACIFIC MOTION SICKNESS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 68. REST OF ASIA-PACIFIC MOTION SICKNESS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 69. REST OF ASIA-PACIFIC MOTION SICKNESS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 70. LAMEA MOTION SICKNESS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 71. LAMEA MOTION SICKNESS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 72. LAMEA MOTION SICKNESS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 73. LAMEA MOTION SICKNESS TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 74. BRAZIL MOTION SICKNESS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 75. BRAZIL MOTION SICKNESS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 76. BRAZIL MOTION SICKNESS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 77. SAUDI ARABIA MOTION SICKNESS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 78. SAUDI ARABIA MOTION SICKNESS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 79. SAUDI ARABIA MOTION SICKNESS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 80. SOUTH AFRICA MOTION SICKNESS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 81. SOUTH AFRICA MOTION SICKNESS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 82. SOUTH AFRICA MOTION SICKNESS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 83. REST OF LAMEA MOTION SICKNESS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 84. REST OF LAMEA MOTION SICKNESS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 85. REST OF LAMEA MOTION SICKNESS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 86. PRESTIGE CONSUMER HEALTHCARE INC.: KEY EXECUTIVES
TABLE 87. PRESTIGE CONSUMER HEALTHCARE INC.: COMPANY SNAPSHOT
TABLE 88. PRESTIGE CONSUMER HEALTHCARE INC.: PRODUCT SEGMENTS
TABLE 89. PRESTIGE CONSUMER HEALTHCARE INC.: PRODUCT PORTFOLIO
TABLE 90. BAXTER INTERNATIONAL INC.: KEY EXECUTIVES
TABLE 91. BAXTER INTERNATIONAL INC.: COMPANY SNAPSHOT
TABLE 92. BAXTER INTERNATIONAL INC.: PRODUCT SEGMENTS
TABLE 93. BAXTER INTERNATIONAL INC.: PRODUCT PORTFOLIO
TABLE 94. NOVARTIS AG: KEY EXECUTIVES
TABLE 95. NOVARTIS AG: COMPANY SNAPSHOT
TABLE 96. NOVARTIS AG: PRODUCT SEGMENTS
TABLE 97. NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 98. WELLSPRING PHARMACEUTICAL CORPORATION: KEY EXECUTIVES
TABLE 99. WELLSPRING PHARMACEUTICAL CORPORATION: COMPANY SNAPSHOT
TABLE 100. WELLSPRING PHARMACEUTICAL CORPORATION: PRODUCT SEGMENTS
TABLE 101. WELLSPRING PHARMACEUTICAL CORPORATION: PRODUCT PORTFOLIO
TABLE 102. AMNEAL PHARMACEUTICALS LLC: KEY EXECUTIVES
TABLE 103. AMNEAL PHARMACEUTICALS LLC: COMPANY SNAPSHOT
TABLE 104. AMNEAL PHARMACEUTICALS LLC: PRODUCT SEGMENTS
TABLE 105. AMNEAL PHARMACEUTICALS LLC: PRODUCT PORTFOLIO
TABLE 106. ABBOTT LABORATORIES: KEY EXECUTIVES
TABLE 107. ABBOTT LABORATORIES: COMPANY SNAPSHOT
TABLE 108. ABBOTT LABORATORIES: PRODUCT SEGMENTS
TABLE 109. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
TABLE 110. SUN PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
TABLE 111. SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
TABLE 112. SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT SEGMENTS
TABLE 113. SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
TABLE 114. VIATRIS INC.: KEY EXECUTIVES
TABLE 115. VIATRIS INC.: COMPANY SNAPSHOT
TABLE 116. VIATRIS INC.: PRODUCT SEGMENTS
TABLE 117. VIATRIS INC.: PRODUCT PORTFOLIO
TABLE 118. VIATRIS INC.: KEY STRATERGIES
TABLE 119. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: KEY EXECUTIVES
TABLE 120. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: COMPANY SNAPSHOT
TABLE 121. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT SEGMENTS
TABLE 122. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT PORTFOLIO
TABLE 123. ZYDUS LIFESCIENCES LIMITED: KEY EXECUTIVES
TABLE 124. ZYDUS LIFESCIENCES LIMITED: COMPANY SNAPSHOT
TABLE 125. ZYDUS LIFESCIENCES LIMITED: PRODUCT SEGMENTS
TABLE 126. ZYDUS LIFESCIENCES LIMITED: PRODUCT PORTFOLIO
TABLE 127. ZYDUS LIFESCIENCES LIMITED: KEY STRATERGIES
*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
